2021 Year in Review: Updates in Biomarker-Driven Lung Cancer | Supplements And Featured Publications

The 2021 Year in Review: Updates in Biomarker-Driven Lung Cancer is the digital version of a print publication encompasses some of the biggest data that have read out in bimarker-driven lung cancer in 2021, along with expert insights in article and video format.

Funding From Daiichi Sankyo/Content Developed Independently by OncLive

Navigating the Nuances of Molecular Testing in NSCLC

January 07, 2022

Charu Aggarwal, MD, MPH, shares how to navigate the nuances of molecular testing in non–small cell lung cancer, key developments made in the treatment of those whose tumors harbor actionable mutations, and the role of PD-L1 expression in informing clinical decisions.

FDA Approvals Signify a Successful 2021 in Lung Cancer, But Resistance to Available Therapies Remains a Top Concern

December 21, 2021

The FDA approvals of several targeted therapies, such as sotorasib, amivantamab-vmjw, and mobocertinib, as well as immunotherapeutic strategies, such as adjuvant atezolizumab, represent significant advances made in 2021 for the treatment of patients with non–small cell lung cancer.